Partnership delivers advanced reverse transcriptase technology to enhance sensitivity, robustness and reproducibility of molecular analysis in clinical, applied and pharmaceutical applications MADISON ...

Nucleoside reverse transcriptase inhibitor exposure is significantly associated with a reduced risk for subsequent development of Alzheimer Disease, reinforcing the idea that inflammasome inhibition ...

Alzheimer's disease is the most common cause of dementia and affects more than a tenth of Americans aged 65 and older. The disease has proven difficult to develop new treatments for, and available ...

One of the hallmarks of many DNA polymerases is that they proofread as they copy DNA, ensuring high-fidelity duplicates of an organism’s genome. This error-checking ability is missing from enzymes ...

Viral reverse transcriptase (RT) plays a critical role in replication (e.g., retroviruses, that reverse transcribe RNA templates into complementary DNA) and genome mutations (e.g., ...

If you're getting treated for an HIV infection, your doctor may suggest a type of drug called an NRTI. It's short for "nucleoside/nucleotide reverse transcriptase ...

Researchers have shown that restoring youthful levels of a telomerase subunit can significantly alleviate aging signs in models, potentially impacting age-related diseases like Alzheimer’s and cancer.

Amid the unprecedented challenges presented by the COVID-19 pandemic, a once obscure enzyme found itself in the spotlight: reverse transcriptase. As laboratories worldwide rushed to develop reliable ...

Joint research led by Yutaro Shuto, Ryoya Nakagawa, and Osamu Nureki of the University of Tokyo determined the spatial structure of various processes of a novel gene-editing tool called “prime editor.

If you’re living with HIV, there are now nine types of antiretroviral therapy (ART) that your doctor may prescribe medication AMong the most common are those called non-nucleoside reverse ...

The global reverse transcriptase enzymes industry has witnessed remarkable growth and is anticipated to further expand, reaching a valuation of US$ 335.0 Million in 2022 and projected to escalate to ...

ROME Therapeutics today announced it will share preclinical data from its lead program, a LINE-1 reverse transcriptase inhibitor, in a poster presentation at American College of Rheumatology (ACR) ...